Sentences with phrase «companies in product liability litigation»

Carlton Fields has represented major manufacturing companies in product liability litigation in state and federal courts nationwide for more than 30 years.

Represented multinational pharmaceutical company in product liability litigation in courts across the country and before the Judicial Panel on Multidistrict Litigation.

Expert development and MDL coordinating counsel for global pharmaceutical company in product liability litigation involving medication to treat gastrointestinal conditions

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

Such risks, uncertainties and other factors include, without limitation: (1) the effect of economic conditions in the industries and markets in which United Technologies and Rockwell Collins operate in the U.S. and globally and any changes therein, including financial market conditions, fluctuations in commodity prices, interest rates and foreign currency exchange rates, levels of end market demand in construction and in both the commercial and defense segments of the aerospace industry, levels of air travel, financial condition of commercial airlines, the impact of weather conditions and natural disasters and the financial condition of our customers and suppliers; (2) challenges in the development, production, delivery, support, performance and realization of the anticipated benefits of advanced technologies and new products and services; (3) the scope, nature, impact or timing of acquisition and divestiture or restructuring activity, including the pending acquisition of Rockwell Collins, including among other things integration of acquired businesses into United Technologies» existing businesses and realization of synergies and opportunities for growth and innovation; (4) future timing and levels of indebtedness, including indebtedness expected to be incurred by United Technologies in connection with the pending Rockwell Collins acquisition, and capital spending and research and development spending, including in connection with the pending Rockwell Collins acquisition; (5) future availability of credit and factors that may affect such availability, including credit market conditions and our capital structure; (6) the timing and scope of future repurchases of United Technologies» common stock, which may be suspended at any time due to various factors, including market conditions and the level of other investing activities and uses of cash, including in connection with the proposed acquisition of Rockwell; (7) delays and disruption in delivery of materials and services from suppliers; (8) company and customer - directed cost reduction efforts and restructuring costs and savings and other consequences thereof; (9) new business and investment opportunities; (10) our ability to realize the intended benefits of organizational changes; (11) the anticipated benefits of diversification and balance of operations across product lines, regions and industries; (12) the outcome of legal proceedings, investigations and other contingencies; (13) pension plan assumptions and future contributions; (14) the impact of the negotiation of collective bargaining agreements and labor disputes; (15) the effect of changes in political conditions in the U.S. and other countries in which United Technologies and Rockwell Collins operate, including the effect of changes in U.S. trade policies or the U.K.'s pending withdrawal from the EU, on general market conditions, global trade policies and currency exchange rates in the near term and beyond; (16) the effect of changes in tax (including U.S. tax reform enacted on December 22, 2017, which is commonly referred to as the Tax Cuts and Jobs Act of 2017), environmental, regulatory (including among other things import / export) and other laws and regulations in the U.S. and other countries in which United Technologies and Rockwell Collins operate; (17) the ability of United Technologies and Rockwell Collins to receive the required regulatory approvals (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the merger) and to satisfy the other conditions to the closing of the pending acquisition on a timely basis or at all; (18) the occurrence of events that may give rise to a right of one or both of United Technologies or Rockwell Collins to terminate the merger agreement, including in circumstances that might require Rockwell Collins to pay a termination fee of $ 695 million to United Technologies or $ 50 million of expense reimbursement; (19) negative effects of the announcement or the completion of the merger on the market price of United Technologies» and / or Rockwell Collins» common stock and / or on their respective financial performance; (20) risks related to Rockwell Collins and United Technologies being restricted in their operation of their businesses while the merger agreement is in effect; (21) risks relating to the value of the United Technologies» shares to be issued in connection with the pending Rockwell acquisition, significant merger costs and / or unknown liabilities; (22) risks associated with third party contracts containing consent and / or other provisions that may be triggered by the Rockwell merger agreement; (23) risks associated with merger - related litigation or appraisal proceedings; and (24) the ability of United Technologies and Rockwell Collins, or the combined company, to retain and hire key personnel.

Prior to joining the firm, Cari represented national companies in litigation for claims involving healthcare, personal injury, contract disputes, and product liability matters.

With deep experience in product liability matters and class action litigation, including catastrophic injury and wrongful death cases, as well as consumer fraud, he represents national and international companies, including manufacturers of motor vehicles, power tools, pharmaceuticals, clothing, glass products, outdoor power equipment, and industrial machinery.

He has many years of experience representing a variety of clients ranging from Fortune 500 companies to small business owners in all phases of litigation including complex commercial cases, corporations, contracts, deceptive trade practices, mass toxic tort cases, premises liability, products liability, and general civil litigation.

In a complex products liability action involving alleged PCB contamination of a state office building, the Appellate Practice Group joined forces with litigation counsel to convert a $ 60 million judgment to a defense verdict for a large, multinational company.

Representation of national construction equipment company in a multi-million dollar asbestos litigation involving successor liability and product identification issues.

Following the U.S. Supreme Court's decision in Wyeth v. Levine that FDA approval does not preempt state tort liability for drug makers, state court decisions like this one will be an important battle ground in pharmaceutical companies» product liability litigation.

Whether in the field of premises liability, product liability, trucking and transportation, automobile liability, construction and / or business litigation claims, I have defended individuals, insurance companies and major corporations in complex litigation within these practice areas.

Luzarraga is also a first chair trial lawyer in product liability and personal injury cases involving automotive companies, consumer product manufacturers, trace benzene and asbestos litigation as well as commercial litigation involving contract disputes, consumer claims, and professional liability.

Led by co-founders and senior partners Mary Quinn Cooper and William S. Leach, ECSL specializes in commercial litigation, products liability, class actions and complex civil litigation on a regional and national level for clients ranging from small privately owned companies and government entities to Fortune 100 companies.

He has also served as National Coordinating Liability Counsel for a major international insurance company with reference to the defense of products liability claims involving thousands of individual claimants and several class actions consolidated in Federal Multi District LiLiability Counsel for a major international insurance company with reference to the defense of products liability claims involving thousands of individual claimants and several class actions consolidated in Federal Multi District Liliability claims involving thousands of individual claimants and several class actions consolidated in Federal Multi District Litigation.

Jake has successfully defended corporations in high exposure product liability cases and has obtained favorable outcomes for individual and corporate entities — from successful small companies to Fortune 100 corporations — in complex business litigation disputes.

As a former partner in a civil litigation defense firm, David defended various Fortune 500 companies in both personal injury and commercial litigation, with an emphasis on product liability and trucking cases.

Prior to joining Lewis Wagner, Meghan was an associate in the New York firm Traub Lieberman Straus & Shrewsberry's insurance coverage group, where she represented insurance company clients in insurance coverage litigation, and advised insurers on exposure and liability issues in wide array of tort and commercial contexts, including mass tort and class action litigation involving pharmaceuticals, chemical, transportation, news and entertainment, and oil and gas; environmental suits; FDA compliance claims; unfair competition and false advertising claims; intellectual property claims; construction defect; personal injury; product liability; and associated breach of contract claims.

Our lawyers have extensive experience in business litigation and appellate law; class actions; construction defect litigation; corporate law and counsel; directors and officers liability; employment counseling and litigation; entertainment law; environmental, Prop 65 and toxic tort liability; estate planning and wealth management; fidelity and surety bonds; insurance coverage, bad faith, ERISA; intellectual property; litigation management, cost control and fee disputes; maritime; mergers and acquisitions; personal and catastrophic injury litigation; product and premises liability; professional negligence; real estate; startup and emerging - growth companies formation and representation; and taxation.

Gary D. White, Jr.'s practice is dedicated to the representation of individuals in tort litigation across the State of Kansas in the areas of automobile negligence, medical malpractice, product liability, wrongful death, federal tort claims, third - party claims against insurance companies, and all other areas of injury litigation.

Prior to joining Shutts & Bowen, Michael served as outside counsel to a Fortune 100 media and entertainment company, handled contractual matters related to the development of new theme park attractions, and also represented clients involved in complex product liability litigation.

Written by John A. Day, Civil Trial Specialist, 2012 Best Lawyers Bet - the - Company Litigation Lawyer of the Year for Nashville and 2012 Best Lawyers in America listed in Personal Injury, Medical Malpractice, Products Liability, Commercial and Bet - the - Company Litigation, Day on Torts identifies more than 300 Tennessee tort law subjects and provides summary of the leading case on each subject to give you a quick, readable synopsis of current state of the law.

He advises large national corporations on complex litigation in the areas of product liability defense, mass tort defense, class action and multidistrict litigation, as well as regional companies and locally owned concerns, in court cases in both state and federal systems.

Since founding the firm, Mr. Palmer has dedicated his practice to the representation of individuals in tort litigation across the State of Kansas in the areas of medical malpractice, product liability, automobile negligence, wrongful death, electrical injuries, federal tort claims, third - party claims against insurance companies, and all other areas of injury litigation.

Vinson & Elkins» San Francisco office focuses on bet - the - company litigation disputes and investigations in the areas of government investigations, antitrust, securities, complex commercial litigation, environmental, complex product liability, class actions, and intellectual property litigation.

He has represented some of America's largest manufacturing companies and financial institutions in their class action litigation throughout Florida and in Multi-District Litigation throughout the country, he advises companies and their Officers and Directors in company investigations and in corporate governance disputes, he represents businesses in disputes with their insurance carriers, and he has represented manufacturers and distributors in hundreds of toxic tort and products liabillitigation throughout Florida and in Multi-District Litigation throughout the country, he advises companies and their Officers and Directors in company investigations and in corporate governance disputes, he represents businesses in disputes with their insurance carriers, and he has represented manufacturers and distributors in hundreds of toxic tort and products liabilLitigation throughout the country, he advises companies and their Officers and Directors in company investigations and in corporate governance disputes, he represents businesses in disputes with their insurance carriers, and he has represented manufacturers and distributors in hundreds of toxic tort and products liability cases.

This is a busy office that represents a lot of the mid-west powerhouse companies in business transactions, intellectual property and litigation, such as commercial, securities, product liability, insurance coverage, and intellectual property matters.

Steven J. Boranian is a partner in Reed Smith's San Francisco office, where he focuses his practice on representing drug and medical device companies in product liability and other kinds of litigation.

The Bryan Cave Product Liability team has substantial experience representing companies from a wide array of industries in product liability litigation involving wrongful death, personal injury and commercial diProduct Liability team has substantial experience representing companies from a wide array of industries in product liability litigation involving wrongful death, personal injury and commercial Liability team has substantial experience representing companies from a wide array of industries in product liability litigation involving wrongful death, personal injury and commercial diproduct liability litigation involving wrongful death, personal injury and commercial liability litigation involving wrongful death, personal injury and commercial disputes.

Over the course of the last 25 years he has been involved in general commercial litigation within the fields of banking, company law, insolvency, professional negligence, franchising, shareholder disputes, disciplinary proceedings before regulatory bodies, tax and VAT cases before the Special Commissioners and VAT Tribunals and product liability.

Summary of Qualifications * Claims Manager for a Fortune 500 company * Hired and trained employees * Handle Claims in the United States and Canada * Involved in quarterly claims review * Reported to the Risk Manager * Implemented Budget * Handled litigation and Arbitration * Liability, general liability, product defect, work comp reviews and suLiability, general liability, product defect, work comp reviews and suliability, product defect, work comp reviews and subrogation